inhibition of the renin-angiotensin system (ACEI or ARB)

Browse trials
V2  
List  

treatment    comparator  All cause death All cause death Coronary death Coronary event Adverse events Cardiovascular death Revascularization Long term death  Non fatal MI stroke (fatal and non fatal)  Death from any cause or hospitalization for any reason hospitalisation for heart failure Cough  Sudden death  cardiovascular events Hypotension  Adverse events leading to treatment discontinuation angiodema death or severe congestive heart failure NYHA class improvement  Hospitalization for any reason cardiovascular death, MI, stroke Hyperkalaemia  death or cardiovascular hospitalization  Cardiovascular death or hospital admission for CHF      
Candesartanheart failure, in patients with preserved-LVEF heart failure vs placebo--------------------------
Irbesartanheart failure, in patients with preserved-LVEF heart failure vs placeboNSNS---NS-----NS--------NS--NS-NS
Telmisartanpatients at high risk for cardiovascular events, in all type of patients vs placeboNSNS-NS-NSNS--NS--NS-NSNSNSNS---NS----
Telmisartanpatients at high risk for cardiovascular events, in all type of patients vs ramiprilNSNS-NS-NSNS--NS-- by 74% -NS by 54% NS by 60% --------
Enalaprilpatients at high risk for cardiovascular events, in all type of patients vs placeboNSNS---NSNS-NSNS----NS-----------
Perindoprilheart failure, in patients with preserved-LVEF heart failure vs placeboNSNS-----NS---NS--------------
Perindoprilpatients at high risk for cardiovascular events, in all type of patients vs placeboNSNS- by 23% -NSNS- by 22% NS-- by 406% - by 19% by 253% by 10% ---------
Quinaprilpatients at high risk for cardiovascular events, in all type of patients vs placeboNSNSNSNS-NSNS-NS-----NS-----------
Ramiprilpatients at high risk for cardiovascular events, in all type of patients vs placebo by 15% by 15% --- by 25% by 13% - by 19% by 31% -- by 301% - by 21% NSNS by 143% --- by 21% ----
Ramiprilpatients at high risk for cardiovascular events, in all type of patients vs ramiprilNSNS-NS-NSNS--NS--NS-NS by 175% by 20% NS--------
Ramiprilpatients at high risk for cardiovascular events, in all type of patients vs telmisartanNSNS-NS-NSNS--NS-- by 323% -NS by 78% by 28% NS--------
Trandolaprilpatients at high risk for cardiovascular events, in all type of patients vs placeboNSNS-NS-NSNS-NSNS----NS------NS----

 


- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons